Research1 week ago 4 min read
PT-141 (bremelanotide) post-marketing follow-up data
Five years of post-approval safety data is summarized in a new review.
by Editorial team
Background
Bremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder in premenopausal women.
It has been on the market since 2019, providing a substantial post-marketing dataset.
What the data shows
The most common adverse events are nausea, flushing, and transient blood pressure elevation.
Severe events have been rare, and the safety profile has remained stable over five years.
Off-label use
The compound is widely used off-label outside the approved indication.
Off-label use lacks the safety monitoring infrastructure of approved use.